HS-10375

Primary Objective: In the dose escalation phase, the safety and tolerability of HS-10375 in subjects with locally advanced or metastatic NSCLC will be evaluated by DLT, MTD, and other indicators. In the dose expansion phase, the efficacy of HS-10375 in subjects with locally advanced or metastatic NSCLC carrying EGFR C797S cis triple mutations (EGFR sensitive mutations < exon 19 deletion or L858R> combined with T790M mutation and cis C797S mutation) and EGFR C797S double mutations (EGFR sensitive mutations < exon 19 deletion or L858R> combined with C797S mutation) will be determined by ORR based on investigator assessment. In the dose extension phase, the efficacy of HS-10375 in subjects with locally advanced or metastatic NSCLC carrying EGFR C797S cis triple mutations will be evaluated by ORR based on IRC assessment.